Alpha 1 antitrypsin deficiency treatment is gaining strategic importance as healthcare systems confront the underdiagnosis of a hereditary condition associated with chronic obstructive pulmonary disease, emphysema, bronchiectasis, liver disease, and, in rare cases, panniculitis. Alpha 1 antitrypsin deficiency results from pathogenic variants in the SERPINA1 gene, leading to low circulating alpha 1 antitrypsin levels or dysfunctional protein that inadequately protects lung tissue from neutrophil elastase-mediated damage. Current care pathways emphasize early diagnosis, smoking avoidance, vaccination, pulmonary rehabilitation, bronchodilator-based respiratory management, treatment of exacerbations, liver monitoring, and intravenous augmentation therapy for eligible adults with severe deficiency and established emphysema. The clinical landscape is also evolving through improved serum level testing, phenotyping, genotyping, family screening, specialty referral networks, home infusion models, and emerging disease-modifying approaches, including RNA-based and gene-targeted strategies. For stakeholders, the central opportunity is not only therapeutic innovation but also earlier identification of patients, standardized care coordination, and evidence-led access strategies that align respiratory, hepatology, immunology, and genetic medicine expertise.

Transformative Shifts in the Treatment Landscape

The alpha 1 antitrypsin deficiency treatment landscape is being reshaped by a shift from symptom-led respiratory care toward precision diagnosis and longitudinal disease management. Historically, many patients have been diagnosed only after years of progressive airflow limitation, but broader use of targeted testing in unexplained COPD, early-onset emphysema, basilar emphysema, liver abnormalities, panniculitis, and family members of affected individuals is improving clinical visibility. Treatment is moving beyond episodic intervention toward integrated care models that combine pulmonary function monitoring, liver assessment, genetic counseling, smoking cessation, vaccination, rehabilitation, and individualized augmentation therapy eligibility review. Another major shift is the growth of decentralized care, including home-based infusion support and remote monitoring, which can reduce treatment burden for patients receiving chronic therapy. Scientific attention is also expanding from protein replacement to approaches intended to reduce hepatic polymer accumulation, increase functional alpha 1 antitrypsin activity, or alter disease progression at the genetic and molecular levels. These changes are raising expectations for stronger diagnostic algorithms, real-world evidence generation, payer-aligned clinical criteria, and multidisciplinary treatment pathways that connect pulmonologists, hepatologists, genetic counselors, infusion providers, and primary care clinicians.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence alpha 1 antitrypsin deficiency treatment by addressing one of the field's most persistent challenges: delayed and missed diagnosis. AI-enabled clinical decision support can analyze electronic health records for patterns such as early-onset COPD, emphysema in nonsmokers, recurrent respiratory infections, unexplained liver enzyme elevation, family history, and low serum alpha 1 antitrypsin results, prompting confirmatory testing where appropriate. In imaging, machine learning tools can support quantitative assessment of emphysema distribution and progression, complementing pulmonary function testing and clinical evaluation. AI can also strengthen patient stratification in research by integrating genotype, phenotype, lung function, imaging, biomarker, and treatment-response data to identify clinically meaningful subgroups. For care delivery, predictive analytics may help flag exacerbation risk, adherence gaps, or infusion scheduling barriers, while natural language processing can extract relevant findings from unstructured clinical notes. The cumulative impact is likely to be highest where AI is governed by validated algorithms, transparent clinical workflows, data privacy safeguards, and equity-focused implementation that avoids reinforcing underdiagnosis in underserved populations. AI should be viewed as an assistive layer that improves case-finding, monitoring, and evidence generation rather than as a replacement for specialist interpretation and shared clinical decision-making.

Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

In Asia-Pacific, alpha 1 antitrypsin deficiency has historically been considered less common than in many Western populations; however, expanding genetic testing, improved COPD phenotyping, and greater awareness of rare respiratory and liver diseases are increasing clinical attention, particularly in urban specialty centers. North America demonstrates comparatively mature diagnostic and treatment infrastructure, supported by established respiratory specialty networks, genetic testing availability, augmentation therapy access pathways, patient registries, and home infusion capabilities, although underdiagnosis remains a persistent barrier among individuals labeled with COPD, asthma, or unexplained liver disease. Latin America is characterized by uneven access to confirmatory testing, specialist care, and chronic infusion services, creating opportunities for targeted clinician education, centralized reference laboratories, and referral protocols for severe or early-onset COPD. Europe benefits from stronger rare disease frameworks, cross-border clinical collaboration, selected newborn and family screening discussions, and established guidance for augmentation therapy eligibility, though reimbursement and testing practices differ across countries. In the Middle East, rising investment in tertiary care, genetic medicine, and respiratory disease management is improving the foundation for alpha 1 antitrypsin deficiency detection, especially where family-based risk assessment and national genomic initiatives support inherited disease identification. Across Africa, limited diagnostic infrastructure and competing health priorities constrain routine detection, but integrated respiratory programs, liver disease evaluation, laboratory capacity building, and telemedicine-supported specialist networks can improve recognition and continuity of care for suspected patients.

Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, alpha 1 antitrypsin deficiency treatment adoption is closely tied to the development of genetic testing capacity, pulmonology referral pathways, and rare disease policy maturity, with large differences between advanced urban hospitals and resource-limited settings. The GCC is positioned to advance case identification through investments in genomic medicine, specialist respiratory centers, premarital and family-based screening models where clinically appropriate, while ensuring that long-term treatment pathways align with national reimbursement structures and infusion service readiness. The European Union provides a strong environment for harmonized rare disease initiatives, cross-country clinical expertise, pharmacovigilance, and evidence-based standards, although national-level reimbursement and implementation still influence patient access. BRICS countries represent a diverse group in which large COPD populations, expanding molecular diagnostics, and growing specialty care capacity can support improved detection, but affordability, geographic access, and care coordination remain critical considerations. G7 countries generally show stronger availability of specialist care, genetic confirmation, clinical guidelines, patient advocacy, and advanced therapeutics infrastructure, making them important environments for real-world evidence and next-generation treatment evaluation. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where military and civilian health systems can benefit from standardized respiratory screening protocols, occupational exposure assessment, smoking cessation programs, and coordinated management of chronic lung disease associated with hereditary risk.

Country Insights Across Major Healthcare Markets

The United States has one of the most developed alpha 1 antitrypsin deficiency care ecosystems, with broad specialist awareness, confirmatory laboratory testing, augmentation therapy pathways, and patient support infrastructure, yet many individuals with COPD or liver disease remain undiagnosed. Canada benefits from public healthcare coordination and respiratory specialty networks, while geographic dispersion creates a need for telehealth-enabled monitoring and equitable infusion access. Mexico and Brazil face opportunities to improve detection through COPD clinics, liver disease programs, and family screening, but access to specialized diagnostics and long-term therapy can vary by region and payer structure. The United Kingdom integrates rare disease expertise with respiratory and hepatology services, supporting structured diagnosis and long-term monitoring, while Germany and France have strong clinical research capacity, specialty networks, and guideline-driven care environments. Russia, Italy, and Spain reflect varying combinations of specialist access, regional healthcare organization, and awareness initiatives, making consistent diagnostic pathways essential for timely identification. China and India have large respiratory disease burdens and expanding genetic testing capabilities, creating significant potential for improved case-finding among patients with unexplained COPD, bronchiectasis, or liver abnormalities, though broad access and clinician awareness remain uneven. Japan, Australia, and South Korea show advanced diagnostic infrastructure and specialist care capacity, with opportunities to strengthen early testing algorithms, family screening, liver surveillance, and real-world evidence collection to guide appropriate treatment selection.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier diagnosis by supporting guideline-aligned testing among patients with COPD, emphysema at a young age, basilar emphysema, unexplained bronchiectasis, chronic liver disease, panniculitis, and family history of alpha 1 antitrypsin deficiency. Care models should integrate pulmonology, hepatology, genetics, primary care, infusion services, and patient education to reduce fragmentation and support lifelong monitoring. Stakeholders should invest in evidence generation that evaluates clinical outcomes, treatment adherence, quality of life, lung function trajectories, exacerbation patterns, liver-related progression, and the real-world impact of home-based care. Diagnostic strategies should combine serum alpha 1 antitrypsin measurement with phenotyping or genotyping to avoid missed cases caused by acute-phase elevation or variant complexity. Access planning should address payer criteria, infusion logistics, rural reach, specialty referral delays, and patient burden. Digital tools, including AI-enabled case-finding, should be clinically validated and implemented with privacy, interoperability, and health equity safeguards. For emerging therapies, leaders should prepare education, biomarker strategies, trial diversity plans, and post-authorization evidence frameworks that reflect the dual lung and liver burden of the disease.

Research Methodology

This executive summary is built on a structured secondary research methodology focused on verified clinical, regulatory, epidemiological, and scientific sources. The approach emphasizes peer-reviewed literature on alpha 1 antitrypsin deficiency genetics, diagnosis, pulmonary and hepatic manifestations, augmentation therapy, monitoring standards, and investigational treatment modalities. It also incorporates publicly available guidance from recognized clinical societies, rare disease authorities, public health agencies, and regulatory bodies, alongside evidence from registries, consensus statements, and real-world clinical studies where available. Source triangulation is used to compare diagnostic recommendations, treatment eligibility criteria, regional access patterns, and emerging technology trends across healthcare systems. The methodology intentionally excludes unsupported market sizing, estimation, share analysis, and forecasting, focusing instead on evidence-backed clinical and strategic insights. Regional, group, and country narratives are interpreted through the lenses of diagnostic infrastructure, specialist availability, reimbursement environment, rare disease policy, genetic testing maturity, and continuity-of-care capabilities.

Conclusion

Alpha 1 antitrypsin deficiency treatment is entering a more precision-driven era defined by earlier testing, multidisciplinary management, improved patient support, and scientific progress toward disease-modifying innovation. While augmentation therapy remains an established option for selected individuals with severe deficiency and emphysema, the broader treatment opportunity lies in identifying patients before irreversible lung damage advances and ensuring coordinated monitoring for both pulmonary and hepatic complications. Regional and country-level differences in diagnostic access, rare disease infrastructure, and long-term therapy delivery continue to shape patient outcomes. Artificial intelligence, real-world evidence, and genomic medicine can accelerate progress when integrated responsibly into validated clinical pathways. The most successful stakeholders will be those that align education, diagnostics, access, evidence generation, and patient-centered care to reduce underdiagnosis and improve the quality and consistency of treatment for alpha 1 antitrypsin deficiency worldwide.

Product Code: MRR-C002B1C99847

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Therapy Class

7.1. Introduction
7.2. Augmentation Therapy
7.3. Gene Therapy
- 7.3.1. AAV Vector
- 7.3.2. Lentiviral Vector
7.4. Plasma Infusion

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Delivery Mode

8.1. Introduction
8.2. Inhalation
8.3. Intravenous

9. Alpha 1 Antitrypsin Deficiency Treatment Market, by Patient Age Group

9.1. Introduction
9.2. Adults
9.3. Geriatrics
9.4. Pediatrics

10. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy

11. Alpha 1 Antitrypsin Deficiency Treatment Market, by End User

11.1. Introduction
11.2. Homecare
11.3. Hospitals
11.4. Specialty Clinics

12. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Alpha 1 Antitrypsin Deficiency Treatment Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Alpha 1 Antitrypsin Deficiency Treatment Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. AstraZeneca PLC
16.2. Baxter International Inc.
16.3. Bayer AG
16.4. Biogen Inc.
16.5. Biotest AG
16.6. Boehringer Ingelheim International GmbH
16.7. CSL Behring GmbH
16.8. GlaxoSmithKline plc
16.9. Grifols S.A.
16.10. Kamada Pharmaceuticals
16.11. Takeda Pharmaceutical Company Limited
16.12. Vertex Pharmaceuticals

Product Code: MRR-C002B1C99847

LIST OF FIGURES

FIGURE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

TABLE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AUGMENTATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AUGMENTATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AUGMENTATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AAV VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AAV VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AAV VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LENTIVIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LENTIVIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LENTIVIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PLASMA INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PLASMA INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PLASMA INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 59. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 60. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 62. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 80. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 81. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 82. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 83. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 84. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 87. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 88. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 94. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 95. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 96. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 97. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 102. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 103. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 104. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 105. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 109. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 110. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 111. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 116. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 123. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 124. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 125. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 126. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 130. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 131. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 132. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 133. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 137. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 138. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 139. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 140. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 144. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 145. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 146. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 147. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 148. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 151. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 152. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 153. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 154. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 159. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 160. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 161. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 162. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 165. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 166. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 167. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 168. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 169. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 172. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 173. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 174. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 175. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 176. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 180. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 181. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 182. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 183. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 186. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 187. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 188. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 189. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 190. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 193. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 194. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 195. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 196. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 197. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 201. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 202. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 203. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 204. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 207. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 208. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 209. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 210. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 211. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 214. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 215. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 216. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 217. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 218. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 222. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 223. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 224. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 225. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 228. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 229. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 230. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 231. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 232. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 235. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 236. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 237. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 238. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 239. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
TABLE 243. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 244. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 245. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 246. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 249. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION